

Plato Income Maximiser Limited Level 35, 60 Margaret Street Sydney NSW 2000 T: 1300 010 311 E: invest@plato.com.au ABN 63 616 746 215

12 December 2022

By Electronic Lodgement

Market Announcements Office ASX Ltd 20 Bridge Street SYDNEY NSW 2000

Dear Sir/Madam

Issue Price and Results of Share Purchase Plan

Plato Income Maximiser Limited (**PL8** or the **Company**) (ACN 616 746 215) confirms that the Share Purchase Plan announced to ASX on 21 November 2022 (**SPP**) closed at 5:00pm on Friday, 9 December 2022. Under the SPP, eligible PL8 shareholders had the opportunity to acquire up to \$30,000 of new fully paid ordinary shares in the Company (**New Shares**).

<u>Issue Price</u>

In accordance with the SPP Terms and Conditions dated 23 November 2022, the Issue Price for the SPP has been determined to be A\$1.11 per New Share. This Issue Price is the lower of :

- A\$1.11, being the pre-tax net tangible asset (**NTA**) of A\$1.078 per fully paid ordinary share in PL8 (**Share**) plus the franking credit balance per Share of A\$0.029, both on 18 November 2022; and
- the pre-tax NTA (A\$1.088) on the day the SPP closed, being Friday, 9 December 2022 plus the franking credit balance per Share of A\$0.029 on 9 December 2022.

Results of the SPP

The Company is pleased to announce that it has accepted valid applications for a total of 77,325,694 New Shares, to raise approximately \$85.8 million pursuant to the SPP. As a result, the net assets of the Company will stand at approximately \$689 million after the additional capital raised under the SPP, making the Company one of the largest listed investment companies on the ASX.

The New Shares will be issued under the SPP on Wednesday, 14 December 2022 and will commence trading on Thursday, 15 December 2022.

New Shares issued under the SPP will rank equally with existing fully paid ordinary shares with effect from their date of issue, including in respect of entitlements to dividends.

The SPP was conducted pursuant to ASX Listing Rule 7.2 (Exception 5). Accordingly, no shareholder approval is required for the issue of the New Shares under the SPP.



The proceeds raised from the SPP will be invested via the Plato Australian Shares Income Fund (ARSN 152 590 157) (**Plato Fund**) in accordance with how the Company's investments are currently structured. Once the proceeds have been invested into the Plato Fund, Plato Investment Management Limited (**Manager**) will, in its capacity as investment manager of the Plato Fund, invest these funds in accordance with the Company's investment strategy in order to deliver on the Company's investment objectives.

Commenting on the SPP, Dr Don Hamson, Director of PL8 and Managing Director of Plato said "We are very pleased with the shareholder support for PL8's SPP evidenced by the amount raised. We are glad that over 4000 shareholders took up the opportunity to invest additional capital in PL8 at closer to NTA.

We continue to see attractive opportunities to deploy the Company's capital and we look forward to deploying the additional capital raised via the SPP that will be invested in the same portfolio and in the same way as the existing assets of the Company. Pleasingly, we expect no impact from the additional capital raised on the monthly fully franked dividend of PL8."

The SPP was not underwritten. However, Taylor Collison Limited acted as authorised intermediary for the SPP.

Issued with the authority of the board of directors.

Shareholder enquiries

Please call Pinnacle Investment Management Limited, the distribution partner of the Company, between 9.00am and 5.00pm (Sydney time) Monday to Friday on 1300 010 311, email invest@plato.com.au or visit invest@plato.com.au or visit invest@plato.com.au or visit

Distribution Partner

Pinnacle Investment Management Limited Level 35, 60 Margaret Street Sydney NSW 2000 1300 010 311

Media contact

Jarrad Brevi
Pinnacle Investment Management Limited media@pinnacleinvestment.com
+61 433 489 870

Share Registry

Automic Pty Ltd Level 5, 126 Philip Street Sydney NSW 2000 hello@automic.com.au 1300 902 587